Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Cystadenocarcinoma, Serous × Topotecan × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 3 Fallopian Tube Neoplasms 3 Small Cell Lung Carcinoma 2 Retinoblastoma 1 Cystadenocarcinoma, Serous 1 Carcinoma, Ovarian Epithelial 1

Interventions

trametinib 1 niraparib 1 liposomal doxorubicin 1 Topotecan 1 Taxes 1 Tamoxifen 1 Paclitaxel 1 Letrozole 1 Doxorubicin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02101788 2025-11-13

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

National Cancer Institute (NCI)

Phase 2/3 Completed

260 enrolled 20 charts

Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon ⚡